Stock Scorecard
Stock Summary for Aclaris Therapeutics Inc (ACRS) - $2.52 as of 11/24/2025 7:52:29 PM EST
Total Score
8 out of 30
Safety Score
27 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for ACRS
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for ACRS
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for ACRS
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for ACRS
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for ACRS (27 out of 100)
| Stock Price Rating (Max of 10) | 3 |
| Historical Stock Price Rating (Max of 10) | 5 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 2 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 4 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 8 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for ACRS
Financial Details for ACRS
Company Overview |
|
|---|---|
| Ticker | ACRS |
| Company Name | Aclaris Therapeutics Inc |
| Country | USA |
| Description | Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Wayne, Pennsylvania, focused on developing innovative small molecule therapies for immuno-inflammatory diseases. With a diverse pipeline of candidates in various clinical trial phases, Aclaris is committed to addressing substantial unmet medical needs through its cutting-edge research and development efforts. The company’s strategic partnerships further enhance its ability to deliver transformative therapies, positioning Aclaris as a forward-thinking leader in the biopharmaceutical landscape dedicated to improving patient outcomes. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 2.52 |
| Price 4 Years Ago | 14.54 |
| Last Day Price Updated | 11/24/2025 7:52:29 PM EST |
| Last Day Volume | 905,851 |
| Average Daily Volume | 1,482,581 |
| 52-Week High | 4.24 |
| 52-Week Low | 1.05 |
| Last Price to 52 Week Low | 140.00% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 43.52 |
| Sector PE | 86.12 |
| 5-Year Average PE | -5.68 |
| Free Cash Flow Ratio | 10.96 |
| Industry Free Cash Flow Ratio | 13.25 |
| Sector Free Cash Flow Ratio | 27.29 |
| Current Ratio Most Recent Quarter | 3.92 |
| Total Cash Per Share | 0.23 |
| Book Value Per Share Most Recent Quarter | 1.11 |
| Price to Book Ratio | 2.26 |
| Industry Price to Book Ratio | 34.10 |
| Sector Price to Book Ratio | 33.20 |
| Price to Sales Ratio Twelve Trailing Months | 17.28 |
| Industry Price to Sales Ratio Twelve Trailing Months | 31.97 |
| Sector Price to Sales Ratio Twelve Trailing Months | 15.80 |
| Analyst Buy Ratings | 4 |
| Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
| Total Shares Outstanding | 108,345,000 |
| Market Capitalization | 273,029,400 |
| Institutional Ownership | 80.28% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -49.26% |
| Reported EPS 12 Trailing Months | -1.58 |
| Reported EPS Past Year | -0.37 |
| Reported EPS Prior Year | -1.51 |
| Net Income Twelve Trailing Months | -141,680,000 |
| Net Income Past Year | -132,065,000 |
| Net Income Prior Year | -88,481,000 |
| Quarterly Revenue Growth YOY | -24.10% |
| 5-Year Revenue Growth | 34.66% |
| Operating Margin Twelve Trailing Months | -517.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 25,256,000 |
| Total Cash Past Year | 24,570,000 |
| Total Cash Prior Year | 39,878,000 |
| Net Cash Position Most Recent Quarter | 25,256,000 |
| Net Cash Position Past Year | 13,917,000 |
| Long Term Debt Past Year | 10,653,000 |
| Long Term Debt Prior Year | 10,653,000 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 0.94 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 155,554,000 |
| Total Stockholder Equity Prior Year | 157,179,000 |
| Total Stockholder Equity Most Recent Quarter | 120,100,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -78,817,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.73 |
| Free Cash Flow Past Year | -20,196,000 |
| Free Cash Flow Prior Year | -79,634,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.10 |
| MACD Signal | 0.09 |
| 20-Day Bollinger Lower Band | 1.37 |
| 20-Day Bollinger Middle Band | 1.96 |
| 20-Day Bollinger Upper Band | 2.54 |
| Beta | 0.64 |
| RSI | 56.99 |
| 50-Day SMA | 1.94 |
| 150-Day SMA | 3.92 |
| 200-Day SMA | 6.69 |
System |
|
| Modified | 11/24/2025 4:27:10 PM EST |